The management of Klebsiella pneumoniae carbapenemase producing (KPC) infections represents a major challenge. Several safety and efficacy concerns are shared by available antibiotics used in KPC infections, leading to the occurrence of serious adverse drug reactions (ADRs), with ceftazidime-avibactam possibly showing a more favourable risk-benefit profile. | Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemaseproducing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study
